Pharmaceuticals & Therapeutics

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Kenai Therapeutics hires a Novartis M&A veteran as CBO, signaling an aggressive strategy to advance its groundbreaking iPSC cell therapy for Parkinson's disease.

A new study links daily mango and avocado to better vascular function, but what does the science—and the funding—really tell us about this fruity fix?

Fastest-growing US professional skincare brand HYDRINITY partners with VeraSeaCosmetics, bringing its regenerative science to France's $5.4B beauty scene.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

As phosphorus becomes a critical U.S. mineral, one firm's tech helps farmers cut fertilizer use by 50% while boosting profits and food security.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

Vico's novel RNA therapy moves to a patient-friendly regimen in Europe and secures FDA clearance for US trials, offering new hope for rare neurological diseases.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.